Remodulin: Uses, Dosage & Side Effects
A prostacyclin analogue for the treatment of pulmonary arterial hypertension (PAH) in adults with moderately severe symptoms
Remodulin (treprostinil) is a prescription prostacyclin analogue used to treat pulmonary arterial hypertension (PAH) in adults with moderately severe symptoms. It works by mimicking naturally occurring prostacyclins – hormone-like substances that relax and widen blood vessels, lower blood pressure in the pulmonary arteries, and prevent blood clots from forming. Remodulin is administered as a continuous subcutaneous or intravenous infusion using a portable external pump or surgically implanted pump. By reducing pulmonary vascular resistance and improving blood flow through the lungs, Remodulin decreases the workload on the right side of the heart, improves exercise capacity, and alleviates symptoms such as breathlessness, dizziness, fatigue, and swelling in the legs and ankles.
Quick Facts: Remodulin
Key Takeaways
- Remodulin (treprostinil) is a prostacyclin analogue used to treat pulmonary arterial hypertension (PAH) by relaxing and widening blood vessels in the lungs, reducing pulmonary artery pressure, and improving blood flow and exercise capacity.
- It is administered as a continuous 24-hour infusion, either subcutaneously (under the skin) via a portable pump or intravenously through a central venous catheter, with doses individually titrated under specialist supervision.
- Treatment must never be stopped abruptly, as sudden discontinuation can cause rapid and potentially life-threatening worsening of PAH symptoms; any dose changes must be gradual and medically supervised.
- The most common side effects include infusion site pain and reactions, headache, jaw pain, nausea, diarrhea, and skin flushing, most of which are related to the drug’s vasodilatory mechanism and often improve over time.
- Remodulin has clinically significant interactions with anticoagulants, antihypertensives, NSAIDs, and drugs that affect CYP2C8 metabolism (such as gemfibrozil and rifampicin), requiring careful monitoring and potential dose adjustments.
What Is Remodulin and What Is It Used For?
Remodulin contains the active substance treprostinil, a stable, chemically synthesized analogue of prostacyclin (also known as prostaglandin I2 or PGI2). Prostacyclin is a naturally occurring hormone-like substance produced by the endothelial cells that line the inner walls of blood vessels. Under normal physiological conditions, prostacyclin plays a critical role in maintaining vascular homeostasis by relaxing smooth muscle cells in blood vessel walls (causing vasodilation), inhibiting the aggregation and adhesion of platelets (preventing blood clot formation), and exerting antiproliferative effects on vascular smooth muscle cells (preventing abnormal vessel wall thickening).
In patients with pulmonary arterial hypertension (PAH), the production and signaling of prostacyclin is severely impaired. This prostacyclin deficiency contributes to the progressive narrowing, stiffening, and remodeling of the small pulmonary arteries, leading to elevated blood pressure within the pulmonary vascular bed. As a result, the right ventricle of the heart must work increasingly harder to pump blood through the lungs, eventually leading to right heart failure if left untreated. The clinical consequences of PAH include progressive breathlessness (dyspnea), dizziness, fatigue, exercise intolerance, fainting episodes (syncope), palpitations, dry cough, chest pain on exertion, and swelling of the ankles and legs (peripheral edema).
Treprostinil addresses the underlying prostacyclin deficiency by acting as a direct agonist at prostacyclin (IP) receptors and, to a lesser extent, at prostaglandin E2 (EP2) receptors on vascular smooth muscle cells and platelets. When treprostinil binds to these receptors, it activates intracellular adenylyl cyclase, increasing levels of cyclic adenosine monophosphate (cAMP). Elevated cAMP leads to relaxation of vascular smooth muscle, resulting in vasodilation of both pulmonary and systemic arterial beds. Simultaneously, increased platelet cAMP inhibits platelet aggregation and adhesion, reducing the risk of in situ thrombosis within the pulmonary vasculature. Additionally, treprostinil has been shown to inhibit the proliferation and migration of vascular smooth muscle cells, potentially slowing the pathological vascular remodeling that characterizes PAH.
Remodulin is indicated for the treatment of idiopathic or hereditary pulmonary arterial hypertension (previously known as primary pulmonary hypertension) in adults with moderately severe symptoms, typically classified as World Health Organization (WHO) Functional Class II or III. Patients in WHO Functional Class II experience slight limitation of physical activity – they are comfortable at rest but develop breathlessness, fatigue, or chest pain with ordinary physical activity. Patients in WHO Functional Class III have marked limitation of physical activity, with symptoms occurring with less-than-ordinary effort but remaining comfortable at rest.
The efficacy of treprostinil in PAH has been demonstrated in several randomized, controlled clinical trials. The pivotal trial was a 12-week, double-blind, placebo-controlled study that enrolled 470 patients with PAH (including idiopathic, familial, and PAH associated with connective tissue disease or congenital heart defects). Patients receiving subcutaneous treprostinil demonstrated statistically significant improvements in the primary endpoint of 6-minute walk distance (6MWD), a well-validated measure of exercise capacity in PAH. Treatment with treprostinil also resulted in improvements in dyspnea scores, hemodynamic parameters (including reductions in pulmonary vascular resistance and mean pulmonary artery pressure), and clinical signs and symptoms of PAH.
Long-term observational studies and registry data have demonstrated that continuous treprostinil infusion can provide sustained clinical benefits over years of treatment, with improvements in functional class, exercise capacity, and hemodynamic parameters maintained in many patients. Treprostinil has also been associated with improved survival outcomes in PAH compared with historical controls, although the interpretation of survival data from non-randomized studies requires caution.
Treprostinil was first approved by the U.S. Food and Drug Administration (FDA) in 2002 for subcutaneous infusion and in 2004 for intravenous infusion. It has subsequently been approved by regulatory authorities in the European Union (marketed by Ferrer Internacional, S.A.) and in many other countries worldwide. Remodulin is also available under other brand names including Trepulmix, Treprostinil Tillomed, and Tresuvi. It represents one of several prostacyclin pathway therapies available for PAH, alongside epoprostenol (Flolan/Veletri), iloprost (Ventavis), and selexipag (Uptravi), each with different routes of administration and pharmacokinetic profiles.
PAH is a serious, progressive condition characterized by abnormally high blood pressure in the arteries connecting the heart to the lungs. Unlike systemic hypertension (high blood pressure measured by a standard blood pressure cuff), PAH specifically affects the pulmonary circulation. Normal mean pulmonary artery pressure is approximately 14 mmHg at rest; PAH is defined as a mean pulmonary artery pressure of 20 mmHg or higher at rest, combined with an elevated pulmonary vascular resistance. Without appropriate treatment, PAH leads to progressive right heart failure and has a significantly reduced life expectancy. Early diagnosis and treatment with targeted therapies like Remodulin are essential for improving outcomes.
What Should You Know Before Using Remodulin?
Contraindications
Remodulin must not be used in patients with any of the following conditions, as the risks clearly outweigh any potential benefits:
- Hypersensitivity: Known allergy to treprostinil or any of the excipients (sodium citrate, sodium chloride, sodium hydroxide, hydrochloric acid, metacresol, or water for injections).
- Pulmonary veno-occlusive disease (PVOD): A rare condition that can mimic PAH but is caused by obstruction of the small veins (rather than arteries) in the lungs. Vasodilator therapy can worsen pulmonary edema in PVOD.
- Severe liver disease: Severely impaired hepatic function may significantly alter treprostinil metabolism and increase the risk of adverse effects.
- Recent myocardial infarction: Heart attack within the last 6 months.
- Severe heart rhythm disturbances: Clinically significant cardiac arrhythmias.
- Severe coronary artery disease or unstable angina: Due to the vasodilatory effects of treprostinil.
- Diagnosed heart defects or untreated heart disease: Structural cardiac abnormalities that may be worsened by vasodilation.
- High risk of bleeding: Including active peptic ulcers, traumatic injuries, intracranial hemorrhage, or other conditions associated with a significant bleeding risk.
- Cerebrovascular accident (stroke): Within the last 3 months.
Warnings and Precautions
Before starting Remodulin, tell your doctor if you have or have ever had any of the following conditions, as they may require special monitoring or dose adjustments:
- Liver disease: Treprostinil is primarily metabolized by the liver (CYP2C8 enzyme). Patients with hepatic impairment may have increased drug exposure, requiring lower starting doses and more cautious dose titration. Your doctor will monitor liver function during treatment.
- Medical obesity (BMI greater than 30): Dosing in obese patients should be based on ideal body weight rather than actual body weight to avoid overdosing. Discuss appropriate dosing with your specialist.
- HIV infection: PAH can occur as a complication of HIV infection. While treprostinil can be used in these patients, the potential for drug interactions with antiretroviral medications should be considered.
- Portal hypertension: PAH associated with portal hypertension (portopulmonary hypertension) has specific treatment considerations. Inform your doctor if you have liver cirrhosis or portal hypertension.
- Congenital heart defects: Patients with congenital systemic-to-pulmonary shunts (such as Eisenmenger syndrome) may respond differently to prostacyclin therapy. Specialist evaluation is essential.
During Remodulin treatment, watch carefully for the following and contact your doctor immediately if they occur:
- Hypotension (low blood pressure): Treprostinil causes vasodilation, which can lower systemic blood pressure. Signs include dizziness, lightheadedness, fainting, and weakness. This is most likely during dose titration.
- Rapidly increasing breathing difficulties or persistent cough: May indicate worsening PAH, pulmonary edema (if PVOD is present), or high cardiac output heart failure.
- Severe or unusual bleeding: Treprostinil inhibits platelet aggregation. Watch for nosebleeds, blood in urine or stool, unusual bruising, or prolonged bleeding from cuts.
- Fever during intravenous administration: May be an early sign of catheter-related bloodstream infection (bacteremia or septicemia), which can be life-threatening. Seek immediate medical attention.
Pregnancy and Breastfeeding
Remodulin is not recommended during pregnancy unless the potential benefit to the mother justifies the potential risk to the fetus. The safety of treprostinil in pregnant women has not been adequately established through clinical studies. Pulmonary arterial hypertension itself carries a very high maternal mortality risk during pregnancy (estimated at 30–50% in historical series), and pregnancy is generally strongly discouraged in women with PAH. Women of childbearing potential should use effective contraception throughout treatment with Remodulin.
It is not known whether treprostinil or its metabolites are excreted in human breast milk. Given the potential for serious adverse effects in the nursing infant, breastfeeding is not recommended during Remodulin therapy. The decision to discontinue breastfeeding or to discontinue Remodulin treatment should take into account the importance of the drug to the mother and the potential risks to the infant.
Driving and Operating Machinery
Remodulin may cause low blood pressure (hypotension), which can lead to dizziness, lightheadedness, or fainting. These effects are most likely during dose initiation and titration periods. If you experience any of these symptoms, do not drive or operate heavy machinery until you know how Remodulin affects you. Once you are on a stable dose and your body has adjusted to the medication, driving and operating machinery may be possible if you do not experience symptoms that could impair your ability to do so safely. Discuss this with your doctor.
Important Information About Ingredients
Remodulin solution for infusion contains sodium. Depending on the volume administered, the maximum daily sodium content can be up to 78.4 mg per 20 ml vial, equivalent to approximately 4% of the WHO recommended maximum daily sodium intake of 2 g for an adult. This is relevant for patients on a sodium-restricted diet. The solution also contains metacresol as a preservative. If you have a known allergy to metacresol or any of the other excipients (sodium citrate, sodium chloride, sodium hydroxide, hydrochloric acid), inform your healthcare provider before starting treatment.
How Does Remodulin Interact with Other Drugs?
Unlike some biological therapies that have minimal drug interactions, treprostinil has several clinically important interactions that healthcare providers must consider. Because treprostinil is metabolized primarily by the cytochrome P450 enzyme CYP2C8 (and to a lesser extent by CYP2C9), drugs that inhibit or induce these enzymes can significantly alter treprostinil blood levels. Additionally, the pharmacodynamic effects of treprostinil – vasodilation and platelet inhibition – can be additive with or potentiate the effects of other drugs with similar actions.
The following table summarizes the most important drug interactions with Remodulin:
| Drug Category | Examples | Interaction Effect | Clinical Action |
|---|---|---|---|
| Antihypertensives / Vasodilators | ACE inhibitors, ARBs, calcium channel blockers, nitrates | Enhanced hypotensive effect; risk of excessive blood pressure lowering | Monitor blood pressure; dose adjustment may be needed |
| Diuretics | Furosemide, hydrochlorothiazide, spironolactone | Additive hypotension; potential electrolyte imbalance | Monitor blood pressure and electrolytes closely |
| Anticoagulants | Warfarin, heparin, nitric oxide-based agents | Increased bleeding risk due to additive antiplatelet and anticoagulant effects | Monitor INR/coagulation; watch for bleeding signs |
| NSAIDs | Aspirin, ibuprofen, naproxen | Increased bleeding risk; potential reduction in renal blood flow | Use with caution; monitor for bleeding and renal function |
| CYP2C8 Inhibitors | Gemfibrozil, trimethoprim, deferasirox | Increased treprostinil plasma levels; enhanced drug effects and side effects | Reduce treprostinil dose; increase monitoring |
| CYP2C8 Inducers | Rifampicin, phenytoin, carbamazepine, phenobarbital, St. John’s wort | Decreased treprostinil plasma levels; reduced therapeutic effect | May require dose increase; avoid St. John’s wort |
The interaction with CYP2C8 inhibitors is particularly important. Gemfibrozil, a fibrate lipid-lowering drug, is a potent inhibitor of CYP2C8 and has been shown to approximately double the exposure (AUC) of treprostinil in pharmacokinetic studies. If gemfibrozil must be used concomitantly with Remodulin, a significant reduction in treprostinil dose may be required, along with intensified monitoring for side effects such as hypotension, headache, nausea, and infusion site reactions.
Conversely, CYP2C8 inducers such as rifampicin (used to treat tuberculosis) can significantly reduce treprostinil blood levels, potentially leading to therapeutic failure and worsening of PAH symptoms. If CYP2C8 inducers are started or stopped during Remodulin therapy, treprostinil dose adjustments will likely be necessary. Herbal preparations containing St. John’s wort (Hypericum perforatum) should be avoided, as this botanical product is known to induce multiple CYP enzymes including CYP2C8.
It is essential to inform your doctor, pharmacist, or nurse about all medications you are currently taking, including prescription drugs, over-the-counter medicines, vitamins, herbal supplements, and dietary products. This allows your healthcare team to identify potential interactions and adjust your treatment plan accordingly.
Many patients with PAH are treated with anticoagulant therapy (most commonly warfarin) because of the increased risk of in situ thrombosis within the pulmonary vasculature. Since treprostinil also inhibits platelet aggregation, the combination of Remodulin with anticoagulants requires careful monitoring of coagulation parameters (INR for warfarin) and clinical assessment for signs of bleeding. Your specialist will determine the appropriate anticoagulation strategy for you.
What Is the Correct Dosage of Remodulin?
Remodulin should always be administered exactly as prescribed by your specialist physician. Treatment with treprostinil requires careful initiation, dose titration, and ongoing monitoring by a physician experienced in the management of pulmonary arterial hypertension. The medication is available in four concentrations (1 mg/ml, 2.5 mg/ml, 5 mg/ml, and 10 mg/ml) to allow flexibility in dosing while minimizing infusion volumes.
Routes of Administration
Remodulin can be administered by three different methods, depending on clinical circumstances and patient preference:
1. Subcutaneous Infusion (Most Common)
The medication is delivered continuously under the skin using a small, portable infusion pump. A thin cannula (small needle) is inserted into the fatty tissue of the abdomen or thigh and secured with a dressing. The pump delivers the undiluted treprostinil solution at a precisely controlled rate, 24 hours a day. The cannula site is typically changed every 2–3 days to minimize infusion site reactions. This is the most commonly used route for Remodulin and allows patients to maintain their daily activities.
2. Intravenous Infusion via External Pump
For patients who cannot tolerate subcutaneous infusion (due to severe infusion site pain, for example), Remodulin can be administered intravenously through a central venous catheter (typically placed in the neck, chest, or groin area) connected to an external portable infusion pump. The solution must be diluted before intravenous use with sterile water for injection or 0.9% sodium chloride solution. Diluted reservoirs should be used within 24 hours.
3. Intravenous Infusion via Implantable Pump
A surgically implanted infusion pump may be placed under the skin of the abdomen. This pump delivers treprostinil continuously through a catheter into a central vein. The implantable pump requires hospital visits approximately every 4 weeks for refilling and dose adjustments. Diluted solution in the implantable pump should be used within 35 days.
Dose Initiation and Titration
Treatment with Remodulin is started at a low dose and gradually increased to find the optimal therapeutic dose for each individual patient:
| Phase | Dose | Duration | Notes |
|---|---|---|---|
| Initiation | 1.25 ng/kg/min | First 1–2 weeks | May be reduced to 0.625 ng/kg/min if not tolerated |
| Titration | Increase by 1.25 ng/kg/min per week | Weeks to months | Guided by symptom improvement and side effects |
| Maintenance | Individually determined (commonly 20–80 ng/kg/min) | Long-term | Continued adjustment as needed; no maximum dose defined |
The rate of dose increase is guided by the patient’s clinical response and tolerability. If side effects such as headache, nausea, jaw pain, or hypotension occur during up-titration, the dose increase may be slowed or temporarily halted until symptoms subside. The goal is to reach a dose that provides optimal improvement in exercise capacity, hemodynamics, and symptoms while maintaining acceptable tolerability.
Special Populations
- Obese patients (BMI > 30): Dosing should be based on ideal body weight rather than actual body weight to avoid excessive drug exposure.
- Hepatic impairment: Patients with liver disease may require lower starting doses and more cautious titration due to reduced treprostinil clearance.
- Children and adolescents: Limited clinical data are available on the use of treprostinil in pediatric patients. Use in this population should only be considered by specialist centers with experience in pediatric PAH.
Interruption of Infusion
Abrupt discontinuation or sudden large dose reductions of treprostinil can cause rapid and severe worsening of PAH symptoms, including potentially life-threatening rebound pulmonary hypertension. Always ensure your pump is functioning properly, your battery is charged, and you have an adequate supply of medication. If interruption is necessary for medical reasons, it must be performed gradually under close specialist supervision.
If treatment with Remodulin needs to be temporarily interrupted (for example, for pump replacement or catheter change), your healthcare team will provide specific instructions. Brief interruptions of minutes to hours may be manageable, but prolonged interruptions carry significant risks. Always carry backup supplies and know how to troubleshoot basic pump problems. Patients and caregivers should receive thorough training on pump operation before starting home therapy.
Overdose
Signs and symptoms of treprostinil overdose are extensions of its pharmacological effects and may include nausea, vomiting, diarrhea, facial flushing (redness), headache, and hypotension (low blood pressure). In the event of suspected overdose, reduce the infusion rate or temporarily stop the infusion and seek immediate medical attention. Treatment is supportive, focusing on maintaining blood pressure and managing symptoms. There is no specific antidote for treprostinil.
What Are the Side Effects of Remodulin?
Like all medicines, Remodulin can cause side effects, although not everyone who uses it will experience them. Many of the common side effects of treprostinil are direct consequences of its pharmacological mechanism of action (vasodilation and platelet inhibition) and are often dose-related, meaning they may be more pronounced during dose titration and may improve as the body adjusts to the medication. Infusion site reactions are particularly common with subcutaneous administration and are a frequent reason for switching to intravenous delivery in some patients.
The following side effects have been observed during clinical trials and post-marketing experience:
Very Common
May affect more than 1 in 10 people
- Vasodilation with skin flushing (facial redness and warmth)
- Pain or redness at the infusion site
- Skin discoloration or bruising at the infusion site
- Headache
- Skin rash
- Nausea
- Diarrhea
- Jaw pain (a characteristic prostacyclin class effect)
Common
May affect up to 1 in 10 people
- Dizziness
- Vomiting
- Lightheadedness or fainting from low blood pressure (hypotension)
- Itching (pruritus) or skin flushing
- Swelling of feet, ankles, and legs (peripheral edema) or fluid retention
- Bleeding episodes (nosebleeds, coughing up blood, blood in urine, gum bleeding, blood in stool)
- Joint pain (arthralgia)
- Muscle pain (myalgia)
- Pain in legs and/or arms (extremity pain)
Not Known
Frequency cannot be estimated from available data
- Infection at the infusion site
- Abscess at the infusion site
- Thrombocytopenia (low platelet count)
- Bleeding at the infusion site
- Bone pain
- Skin flushing with discoloration or raised bumps
- Cellulitis (skin and soft tissue infection)
- High cardiac output heart failure (leading to breathlessness, fatigue, leg/abdominal swelling, persistent cough)
Side Effects Specific to Intravenous Administration
Patients receiving Remodulin via intravenous infusion through a central venous catheter are at risk of additional side effects related to the catheter itself:
- Phlebitis: Inflammation of the vein around the catheter, which can cause pain, redness, and swelling at the catheter site.
- Bacteremia and septicemia: Bacterial infection of the bloodstream, which can be serious and potentially life-threatening or fatal. Cases of fatal bloodstream infections have been reported in patients receiving intravenous treprostinil. Signs of bloodstream infection include fever, chills, low blood pressure, and general malaise. Strict aseptic (sterile) technique during catheter care and solution preparation is essential to minimize this risk.
Infusion site pain is the most commonly reported side effect with subcutaneous Remodulin and is the primary reason some patients are switched to intravenous delivery. The pain typically occurs at the cannula insertion site and can range from mild discomfort to severe, persistent pain. Strategies to manage infusion site pain include rotating the infusion site regularly, using topical anesthetics (such as lidocaine cream) before cannula insertion, applying warm or cold compresses, and using anti-inflammatory medications as directed by your doctor.
Jaw pain is a well-recognized class effect of prostacyclin analogues and is thought to result from vasodilation of blood vessels in the jaw and facial region. It is typically most noticeable during eating or when opening the mouth widely. Jaw pain often diminishes over time as the body adjusts to the medication.
Contact your doctor or seek emergency care immediately if you experience: fever during intravenous infusion (possible bloodstream infection), severe or unusual bleeding, sudden worsening of breathlessness, chest pain, fainting, or signs of severe allergic reaction (difficulty breathing, swelling of the face or throat, widespread rash). If your pump stops working or you suspect a significant dose interruption, contact your PAH specialist center immediately.
How Should You Store Remodulin?
Proper storage and handling of Remodulin are essential to maintain the medication’s quality, safety, and efficacy. Treprostinil solution for infusion has specific storage requirements that vary depending on whether the vial is unopened, opened, or diluted for infusion.
| Condition | Storage Requirement | Maximum Duration |
|---|---|---|
| Unopened vials | No special storage requirements | Until expiry date on label |
| Opened vials | Keep at room temperature | 30 days after opening |
| SC infusion (undiluted reservoir) | Room temperature | 72 hours |
| IV external pump (diluted) | Room temperature | 24 hours |
| IV implantable pump (diluted) | Body temperature (implanted) | 35 days |
Additional storage guidelines include:
- Keep out of sight and reach of children.
- Do not use after the expiry date printed on the vial label and outer carton.
- Inspect before use: Do not use if the vial is damaged, the solution is discolored, cloudy, or shows signs of deterioration. The solution should be colorless to slightly yellow.
- Color-coded caps: Remodulin vials are distinguished by color-coded caps to help identify the concentration: yellow (1 mg/ml), blue (2.5 mg/ml), green (5 mg/ml), and red (10 mg/ml). Always verify the concentration before use.
- Dilution for IV use only: When preparing Remodulin for intravenous infusion, dilute with sterile water for injection or 0.9% sodium chloride solution only. Do not mix with other medications.
- Single vial, multiple use: Each vial is designed for use by a single patient but can be used for multiple refills within the 30-day period after opening, provided aseptic technique is maintained.
What Does Remodulin Contain?
Understanding the composition of Remodulin is important for identifying potential allergens and for proper preparation of the infusion solution. The medication is supplied in four different concentrations to accommodate varying dose requirements while maintaining practical infusion volumes.
| Ingredient | Role | Notes |
|---|---|---|
| Treprostinil | Active substance (prostacyclin analogue) | 1, 2.5, 5, or 10 mg per ml |
| Sodium citrate | Buffer (pH stabilizer) | Maintains solution pH for stability |
| Sodium chloride | Tonicity agent | Adjusts osmolality of solution |
| Sodium hydroxide | pH adjustment | Used to adjust solution pH |
| Hydrochloric acid | pH adjustment | Used to adjust solution pH |
| Metacresol | Preservative | Allows multi-dose use of vial; potential allergen |
| Water for injections | Solvent | Volume to 20 ml per vial |
Appearance and Pack Sizes
Remodulin is supplied as a colorless to slightly yellow, clear solution in 20 ml clear glass vials. The vials are sealed with rubber stoppers and have color-coded flip-off caps to identify the concentration:
- Yellow cap: 1 mg/ml (20 mg per vial)
- Blue cap: 2.5 mg/ml (50 mg per vial)
- Green cap: 5 mg/ml (100 mg per vial)
- Red cap: 10 mg/ml (200 mg per vial)
Remodulin is manufactured and marketed by Ferrer Internacional, S.A. It is also available under the brand names Trepulmix, Treprostinil Tillomed, and Tresuvi from other manufacturers. Availability of specific concentrations and pack sizes may vary by country.
Frequently Asked Questions About Remodulin
Remodulin (treprostinil) is used to treat pulmonary arterial hypertension (PAH), a serious condition characterized by abnormally high blood pressure in the arteries connecting the heart to the lungs. It is indicated for adults with idiopathic or hereditary PAH who have moderately severe symptoms (WHO Functional Class II or III). By mimicking natural prostacyclin, Remodulin relaxes and widens blood vessels in the lungs, reduces pulmonary artery pressure, improves blood flow, and decreases the workload on the right side of the heart. This leads to improvements in exercise capacity, breathlessness, fatigue, and other PAH symptoms.
Remodulin is a prostacyclin pathway therapy, which is one of three main treatment pathways for PAH (alongside the endothelin pathway and the nitric oxide pathway). What distinguishes Remodulin from other prostacyclin therapies is its chemical stability at room temperature (unlike epoprostenol, which requires cold chain storage), its longer half-life of 2–4 hours (compared to minutes for epoprostenol), and the option for subcutaneous administration (avoiding the need for a central venous catheter). Compared to oral PAH therapies, Remodulin provides continuous drug delivery and is often considered for patients who are not adequately controlled on oral medications alone, as part of combination therapy strategies recommended by current ESC/ERS guidelines.
Infusion site reactions (pain, redness, swelling, bruising) are the most common side effect of subcutaneous Remodulin and can begin within hours of starting the infusion at a new site. In many patients, the severity of infusion site pain tends to decrease over weeks to months as the body adjusts to the medication. However, for some patients, infusion site pain remains a significant ongoing challenge. Strategies to manage these reactions include rotating the infusion site every 2–3 days, using topical lidocaine cream before inserting the cannula, applying warm or cold compresses, and working with your care team to optimize the infusion setup. If subcutaneous infusion site pain remains intolerable, your doctor may consider switching to intravenous administration.
Yes, many patients on Remodulin travel successfully, but careful planning is essential. You should carry sufficient medication, pump supplies, and backup equipment for the duration of your trip plus additional days in case of delays. Obtain a letter from your doctor explaining your medical condition and the need for your infusion pump and supplies (important for airport security and border crossings). Be aware that altitude changes (such as during flights) can affect pump function, and discuss this with your specialist before traveling. Identify PAH specialist centers at your destination in case of emergencies. Air travel is generally possible but you should check with your airline regarding policies for carrying medical devices and injectable medications.
A pump malfunction is a medical urgency because abrupt discontinuation of treprostinil can cause dangerous rebound pulmonary hypertension. If your pump stops delivering medication, immediately contact your PAH specialist center or go to the nearest emergency department. You should always carry a backup pump (if available) or at minimum have access to one. Your care team should provide you with an emergency plan that includes troubleshooting basic pump issues, contact numbers for your specialist center (available 24/7), and instructions for temporary dose management. Many PAH centers also recommend keeping emergency oral or inhaled prostacyclin medications available for bridge therapy during pump emergencies.
Yes, current international guidelines (ESC/ERS 2022) recommend combination therapy for most patients with PAH. Remodulin (targeting the prostacyclin pathway) is frequently combined with medications targeting other pathways, such as endothelin receptor antagonists (bosentan, ambrisentan, macitentan) and phosphodiesterase-5 inhibitors (sildenafil, tadalafil) or soluble guanylate cyclase stimulators (riociguat). Triple combination therapy (using all three pathways) is increasingly used in patients with inadequate response to dual therapy. Your specialist will determine the most appropriate combination based on your disease severity, functional class, and hemodynamic profile. Always inform your specialist about all medications you are taking to ensure safe combinations.
References
- European Medicines Agency (EMA). Remodulin (treprostinil) – Summary of Product Characteristics. Last updated 2025. Available at: EMA Remodulin EPAR.
- U.S. Food and Drug Administration (FDA). Remodulin (treprostinil) – Prescribing Information. United Therapeutics Corporation. Revised 2024.
- Simonneau G, Barst RJ, Galie N, et al. Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension: A Double-Blind, Randomized, Placebo-Controlled Trial. Am J Respir Crit Care Med. 2002;165(6):800–804. doi:10.1164/ajrccm.165.6.2106079.
- Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Eur Heart J. 2022;43(38):3618–3731. doi:10.1093/eurheartj/ehac237.
- Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006;28(6):1195–1203. doi:10.1183/09031936.06.00044406.
- Sadushi-Kolici R, Jansa P, Galiè N, et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med. 2019;7(3):239–248. doi:10.1016/S2213-2600(18)30367-9.
- World Health Organization (WHO). Pulmonary Hypertension. Classification and Pathophysiology. WHO Technical Report. 2023.
- Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. doi:10.1183/13993003.01889-2018.
- Frost AE, Badesch DB, Miller DP, Benza RL, Meltzer LA, McGoon MD. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. Chest. 2013;144(5):1521–1529.
- British National Formulary (BNF). Treprostinil. National Institute for Health and Care Excellence (NICE). 2025.
About Our Medical Team
All content on iMedic is created and reviewed by qualified medical professionals following international evidence-based guidelines. Our editorial process ensures accuracy, currency, and clinical relevance.
Medical Content Team
Specialists in pulmonary medicine, cardiology, and clinical pharmacology with extensive experience in pulmonary hypertension management and prostacyclin-based therapies.
Medical Review Board
Independent panel of board-certified physicians who verify all medical claims against current evidence and international guidelines (WHO, EMA, FDA, ESC/ERS).
Editorial Standards
All content follows the GRADE evidence framework and is based on Level 1A evidence from systematic reviews and randomized controlled trials where available.
Independence
iMedic receives no pharmaceutical company funding or sponsorship. All content is editorially independent, ensuring unbiased medical information for patients and caregivers.